UNSPSC 51162502: Ammonium chloride/antimony potassium tartrate/ipecac

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE302. This VA Drug Class (RE302) classifies this compound as belonging to the group NON-OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51162502 Ammonium chloride/antimony potassium tartrate/ipecac is a Commodity code whose recent state and local activity does not align with its nominal scope. The two posted opportunities under this code — Seminole County, Florida's procurement of naloxone and drug deactivation systems, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and over-the-counter products — fall outside the emetic and antimony-based pharmaceutical compounds the code nominally covers. The MMCAP solicitation represents cooperative purchasing spanning multiple participating state and local government facilities, including Oregon, and targets manufacturers willing to supply generic pharmaceuticals through authorized wholesalers with fixed or net-price pricing structures. The Seminole County opportunity seeks annual procurement of naloxone units and drug deactivation systems for community health initiatives. Neither opportunity maps to the code's abstract definition, suggesting the code may be misapplied in state and local procurement systems or sees minimal relevant activity.

Solicitation activity under this code centers on Florida and Minnesota. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and includes a two-year initial term with one-year renewal option. The MMCAP RFP (S1070000015802), posted January 20, 2026, with a proposals-due date of March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products across state and local participants, with products required to be available in the marketplace by May 15, 2026, and resulting agreements effective July 1, 2026. Both solicitations require vendor compliance with federal regulations, insurance requirements, and drug-supply security standards, though neither specifies explicit set-aside designations for disadvantaged enterprises.